Direct thrombin inhibitors

Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 83-96

  Bittl, John A ^a   White, Harvey D ^b   Antman, Elliott M ^c  

^a Munroe Regional Med Center   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904027946     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0408-4.50013-5     Document Type: Chapter

References (85)

1. Antman EM, Bittl JA Direct thrombin inhibitors. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease 1999, 145-165. WB Saunders, Philadelphia. C.H. Hennekens, J.E. Buring, J.E. Manson (Eds.).
2. Antman EM The search for replacements for unfractionated heparin. Circulation 2001, 103:2310-2314.
3. Greinacher A, Lubenow N Recombinant hirudin in clinical practice: Focus on lepirudin. Circulation 2001, 103:1479-1484.
4. Weitz JI, Buller HR Direct thrombin inhibitors in acute coronary syndromes: Present and future. Circulation 2002, 105:1004-1011.
5. Califf RM Publication policy, informed consent, and the randomized clinical trial. Am Heart J 2002, 143:187-188.
6. Wilcox JN, Smith KN, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci 1989, 86:2839-2843.
7. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995, 91:619-622.
8. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996, 380:41-46.
9. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human athersclerotic plaques. Circulation 1997, 95:594-599.
10. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: Heparin. A statement for healthcare professionals from the American Heart Association. Circulation 2001, 103:2994-3018.
11. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992, 326:287-291.
12. Marmur JD, Merlinie PA, Sharma SK, et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994, 24:1484-1491.
13. Coughlin SR, Vu TK, Hung DT, et al. Characterization of a functional thrombin receptor. J Clin Invest 1992, 89:351-355.
14. Coughlin S Thrombin signaling and protease-activated receptors. Nature 2000, 407:258-264.
15. Hirsh J, Fuster V Guide to anticoagulant therapy: Part I: Heparin. Circulation 1994, 89:1449-1468.
16. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
17. Eitzmann DT, Chi L, Saggin L, et al. Heparin neutralization by platelet-rich thrombi: Role of platelet factor 4. Circulation 1994, 89:1523-1529.
18. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998, 31:1449-1459.
19. Xiao Z, Théroux P Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97:251-256.
20. Kelly AB, Maraganore JM, Bourdon P, et al. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 1992, 89:6040-6044.
21. The Direct Thrombin Inhibitor Trialists' Collaborative Group Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 2002, 359:294-302.
22. Vanholder R, Dhondt A Recombinant hirudin: Clinical pharmacology and potential applications in nephrology. Biol Drugs 1999, 11:417-429.
23. Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999, 100:1528-1532.
24. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000, 96:2238-2373.
25. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29:7095-7101.
26. Gold HK, Johns JA, Leinbach RC, et al. A randomized, blinded, placebo-controlled trial of recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. 1987, 75:1192-1199.
27. Libby P Current concepts in the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
28. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994, 23:993-1003.
29. Lee LV Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 Trial. TIMI 6 Investigators. Am J Cardiol 1995, 75:7-13.
30. Antman EM Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. TIMI 9B Investigators. Circulation 1996, 94:911-921.
31. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775-782.
32. Simes RJ, Granger CB, Antman EM, et al. Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes: A prospective meta-analysis of the GUSTO-IIb and Timi 9b Trials (abstract). Circulation 1996, 94(I):I-430.
33. Antman E, for the TIMI 9A Investigators Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994, 90:1624-1630.
34. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637.
35. Neuhaus KL, v Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALK). Circulation 1994, 90:1638-1642.
36. Théroux P, Pérez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995, 91:2132-2139.
37. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997, 96:2155-2161.
38. White HD: Hirulog Early Reperfusion and Occlusion 2 Trial (HERO 2), European Society of Cardiology, Stockholm, September 3, 2001, 2001.
39. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605-613.
40. Topol EJ Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001, 357:1905-1914.
41. White HD, Chew DP Bivalirudin: An anticoagulant for acute coronary syndromes and coronary interventions. Expert Opin Pharmacother 2002, 3:777-788.
42. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI Study. J Thromb Thrombolysis 2000, 10:233-240.
43. The Prime Investigators Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am Heart J 2002, 143:95-105.
44. Braunwald E Unstable angina. A classification. Circulation 1989, 80:410-414.
45. Ahmed WH, Bittl JA, Braunwald E Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol 1993, 72:544-550.
46. Organisation to Assess Strategies for Ischemic Syndromes (OASIS) Investigators Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation 1997, 96:769-777.
47. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: A randomised trial. Lancet 1997, 353:429-438.
48. Fuchs J, Cannon CP, the TIMI 7 Investigators Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial. Circulation 1995, 92:727-733.
49. Antman EM, McCabe CH, Braunwald E Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 Trial. Am Heart J 2002, 143:229-234.
50. White HD Improved efficacy and less bleeding: Further evidence of a unique uncoupling of benefit and risk with bivalirudin. Am Heart J 2002, 143:189-192.
51. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039-1047.
52. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. Lancet 1999, 352:2019-2024.
53. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl J Med 1994, 330:956-961.
54. The EPILOG Investigators Evaluation of PTCA to Improve Long-Term Outcome by c7E3 Glycoprotein IIb/IIIa Receptor Blockade (EPILOG). N Engl J Med 1997, 336:1689-1696.
55. Narins CR, Hillegass WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996, 93:660-671.
56. McGarry TF, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992, 123:1445-1451.
57. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994, 23:1061-1065.
58. Bittl JA, Ahmed WH Relation between the risk of abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998, 82:50P-56P.
59. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal ACT during percutaneous coronary intervention: Aggregate results from six randomized controlled trials. Circulation 2001, 103:961-966.
60. Serruys PW, Herrman J-PR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757-763.
61. Manfredi JA, Wall RP, Sane DC, et al. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary interventions: Case reports. Cath Cardiovasc Intervent 2001, 52:468-472.
62. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629.
63. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995, 333:764-769.
64. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final report of the Bivalirudin Angioplasty Study. Am Heart 2001, 142:952-959.
65. Bittl JA, Feit F A randomized comparison of bivalirudin and heparin in patients undergoing angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 1998, 82:43P-49P.
66. Strony J, Ahmed WH, Meckel CR, et al. Clinical evidence for thrombin rebound after stopping heparin but not Hirulog (abstract). Circulation 1995, 92:I-609.
67. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002, 143:847-853.
68. Lincoff AM, Bittl JA, Kleiman NS, et al. The REPLACE 1 Trial: A pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade (abstract). J Am Coll Cardiol 2002, 39. in press.
69. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein blockade during percutaneous coronary intervention. JAMA 2003, 289:1638.
70. Suzuki S, Matsuo T, Kobayashi H, et al. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: Effects on inflammatory, hemostatic, and endothelium-derived parameters. Thromb Res 2000, 98:269-279.
71. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cath Cardiovasc Intervent 2002, 57:177-184.
72. Aster RH Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995, 332:1374-1376.
73. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
74. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia [see comments]. Ann Intern Med 1997, 127:804-812.
75. Koster A, Meyer O, Hausmann H, et al. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery. J Clin Anesth 2000, 12:324-327.
76. Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995, 11:511-514.
77. Reid T Hirulog therapy for heparin-associated thrombocytopenia and deep venous thrombosis (letter). Am J Hematol 1994, 45:352-353.
78. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
79. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997, 337:1329-1335.
80. Ginsburg JS, Nurmohaned MT, Gent M, et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994, 90:2385-2389.
81. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002, 137:648-655.
82. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelegatran and melagatran compared with dalteparin for prevention of deep venous thrombosis after total hip of knee replacement: The METHRO II randomised trial. Lancet 2002, 360:1441-1447.
83. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999, 100:587-593.
84. Argatroban for treatment of heparin-induced thrombocytopenia. Med Let Drugs Ther 2001, 43:11-12.
85. Petersen P, Grind M, Adler J, et al. Ximelegatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: A dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003, 41:1445-1451.